HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: thx.2006.061366v1 61/11/969    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Block, J K Articles by Aaron, S D Search for Related Content PubMed PubMed Citation Articles by Block, J K Articles by Aaron, S D Topic Collections Relevant Article

Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria

¹ Ottawa Health Research Institute, University of Ottawa, Ottawa, ON, Canada
² Woolcock Institute, Sydney, NSW, Australia
³ St Michael’s Hospital, Toronto, ON, Canada
⁴ Dalhousie University, Halifax, NS, Canada
⁵ Universite de Montreal, Montreal, QC, Canada
⁶ University of Alberta, Edmonton, AB, Canada
⁷ University of British Columbia, Vancouver, BC, Canada
⁸ The Prince Charles Hospital, Brisbane, Qld, Australia
⁹ Memorial University, St John’s, NF, Canada
¹⁰ McMaster University, Hamilton, ON, Canada
¹¹ University of Western Ontario, London, ON, Canada

Correspondence to:
Correspondence to:
Dr S D Aaron
Ottawa Hospital, General Campus, 501 Smyth Road, Mailbox 211, Ottawa, Ontario, Canada K1H 8L6; saaron{at}ottawahospital.on.ca

Background: This study examined characteristics of adult and adolescent patients with cystic fibrosis (CF) to determine factors associated with an increased risk of pulmonary exacerbations.

Methods: 249 patients with CF infected with multidrug resistant bacteria were recruited and prospectively followed for up to 4.5 years until they experienced a pulmonary exacerbation severe enough to require intravenous antibiotics. Multivariable regression analyses were used to compare the characteristics of patients who experienced an exacerbation with those who did not.

Results: 124 of the 249 patients (50%) developed a pulmonary exacerbation during the first year and 154 (62%) experienced an exacerbation during the 4.5 year study period. Factors predictive of exacerbations in a multivariable survival model were younger age (OR 0.98, 95% CI 0.96 to 0.99), female sex (OR 1.45, 95% CI 1.07 to 1.95), lower forced expiratory volume in 1 second (FEV₁) (OR 0.98, 95% CI 0.97 to 0.99), and a previous history of multiple pulmonary exacerbations (OR 3.16, 95% CI 1.93 to 5.17). Chronic use of inhaled corticosteroids was associated with an increased risk of exacerbation (OR 1.92, 95% CI 1.00 to 3.71) during the first study year.

Conclusions: Patients who experience pulmonary exacerbations are more likely to be younger, female, using inhaled steroids, have a lower FEV₁, and a history of multiple previous exacerbations. It is hoped that knowledge of these risk factors will allow better identification and closer monitoring of patients who are at high risk of exacerbations.

Abbreviations: BMI, body mass index; CF, cystic fibrosis; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity

Keywords: cystic fibrosis; pulmonary exacerbations; bacterial resistance; lung infections; risk factors

Relevant Article

Airwaves

Wisia Wedzicha
Thorax 2006 61: 923. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				N. A. Jarad and K. Giles Risk factors for increased need for intravenous antibiotics for pulmonary exacerbations in adult patients with cystic fibrosis Chronic Respiratory Disease, February 1, 2008; 5(1): 29 - 33. [Abstract] [PDF]

				M. B. Dolovich and D. P. Schuster Positron Emission Tomography and Computed Tomography versus Positron Emission Tomography Computed Tomography: Tools for Imaging the Lung Proceedings of the ATS, August 1, 2007; 4(4): 328 - 333. [Abstract] [Full Text] [PDF]

				S. C Bell and P. J Robinson Exacerbations in cystic fibrosis: 2 {middle dot} Prevention Thorax, August 1, 2007; 62(8): 723 - 732. [Abstract] [Full Text] [PDF]